Nanose Medical
Frontline Risk Stratification with Breath Biomarkers & Proprietary AI Algorithms
Company Overview
Snapshot
Founded in October 2019 by Orit Marom Albeck, Ilay Marom, Osnat Sella Tavor, and Prof. Hossam Haick, Nanose Medical operates with 1-10 employees. The company has raised $10.58 million across 7 funding rounds. In May 2024, the company received a grant from the European Innovation Council.
Business overview
Nanose Medical develops non-invasive, AI-driven breath-sensing devices for early disease detection and risk stratification. Their technology identifies unique biomarker fingerprints in breath, with current applications focused on screening for lung cancer and advanced liver fibrosis (MASH). The company aims to provide affordable, accurate point-of-care screening solutions, addressing critical gaps in diagnostics where existing methods are often invasive, expensive, or underused. Nanose Medical operates within the Health Tech & Life Sciences sector, specifically targeting medical devices and diagnostics, and serves healthcare providers.
Strategic signal
In May 2025, Nanose Medical was noted for its resilience and adaptability during a panel at Google and Calcalist’s Startup Week. Despite geopolitical challenges, the company secured grants from the European Union, Israel Innovation Authority, and Google, advancing its development timeline. This signals strong investor confidence and operational robustness, indicating the company's ability to navigate external pressures while progressing its clinical trials and product development.
Log in to access full profile ›Company Intelligence Q&A
- What is Nanose Medical's core technology?
- Nanose Medical utilizes a non-invasive, AI-driven breath-sensing device that detects unique biomarker fingerprints. This technology is currently applied for screening lung cancer and advanced liver fibrosis (MASH).
- When did Nanose Medical receive a grant from the European Innovation Council?
- In May 2024, Nanose Medical received a grant from the European Innovation Council.
- What was the focus of Nanose Medical's poster presentation at the EASL SLD Summit 2025?
- In January 2025, Nanose Medical presented a poster titled "Novel point-of-care, rapid breath test to identify patients with metabolic dysfunction associated steatotic liver disease with advanced fibrosis – a pilot study" at the EASL SLD Summit.
- Which organizations provided support to Nanose Medical in early 2024?
- In January 2024, Nanose Medical received support from the.
- What was a key highlight for Nanose Medical at Google and Calcalist’s Startup Week in May 2025?
- In May 2025, Nanose Medical showcased its resilience and adaptability during a panel at Google and Calcalist’s Startup Week, highlighting its ability to stabilize financially and advance its development timeline despite external challenges, supported by grants from the European Union, Israel Innovation Authority, and Google.